The general meeting
The 68th BAH General Assembly took place for the first time since the start of the pandemic as a precision event on September 27 & 28, 2022 in Berlin and was full of highlights: new projects such as the BAH podcast "Healthy Perspectives", new faces on the BAH Board, the first award for Sustainability in the pharmaceutical industry in Germany and Europe, and stimulating and important discussions on political developments.
On Tuesday at noon, Chairman of the Board Jörg Wieczorek opened the internal part at the Meliá Hotel International Berlin with a speech outlining the historical challenges that are shaking the pharmaceutical industry. This was followed by an overview by Chief Executive Officer Dr. Hubertus Cranz of the association's activities over the past year and the election of the three new board members Katja Pütter-Ammer of MEDICE Arzneimittel Pütter GmbH & Co. KG, Theresa von Fugler of Sanofi Conusmer Healthcare Germany and Sebastian Wachtarz of AbbVie.
In the afternoon, the first award for sustainability in the pharmaceutical industry in Germany and Europe was presented. An independent jury led by Prof. Stefan Schaltegger of CSM Leuphana University of Lueneburg chose from 25 projects.
Sabine Leutheusser-Schnarrenberger, former Federal Minister of Justice and Deputy Chairwoman of the Friedrich Naumann Foundation for Freedom, Mechthild Kaub of the Bund Für Umwelt Und Naturschutz BUND and Prof. Ortwin Renn from the Institute for Advanced Sustainability Studies (IASS) in Potsdam, congratulated three winners on their success: Salus, Weleda AG and ORION Pharma GmbH were honored by the jury for sustainability projects that are characterized by a very high degree of ecological, environmental and climate-conscious responsibility.
In the evening, the health politicians from the German parliamentary groups Martina Stamm-Fibich, Member of the German Social Democratic Party (SPD), Prof. Andrew Ullmann, Member of the German Free Democratic Party (FDP), Tino Sorge, Member of the German Christian Democratic Union (CDU) and Christian Social Union (CSU), and Dr. Paula Piechotta, Member of the German Parliament, BÜNDNIS 90/DIE GRÜNEN met at the AXICA Eventlocation to discuss current concerns such as the GKV-Finanzstabilisierungsgesetz and AMNOG and to answer the questions of the attendees.
Wednesday was opened by Prof. Edgar Franke, Parliamentary State Secretary at the Federal Ministry of Health, with a greeting from the Federal Government to our industry. Afterwards, several panels discussed in detail where the health policy journey is headed in the topics of Switch, medical product|es, Europe and digitalization - among others, Thomas Mueller from the Federal Ministry of Health and Dr. Bassil Akra from AKRA TEAM GmbH were represented. But the last word again belonged to our Chairman of the Board Jörg Wieczorek, who, in view of the exciting and open discussions, was confident that Germany's healthcare policy, also with the help of the BAH, will continue to find solutions in the future that will ensure a good, safe and future-oriented supply of medicines.
The BAH hosted its 67th General Meeting digitally on September 30, 2021. It was broadcast live from RTL's capital city studio. Participants from member companies had the opportunity to receive information on current health policy topics and to actively participate in the association's work.
During the internal part of the event, one of the items on the agenda was the election of the board of directors. Dr. Dorothee Brakmann of Janssen-Cilag and Stefan Brinkmann of Merz Pharmaceuticals were newly elected to the board, Jan Kuskowski, Dr. Ralf Mayr-Stein, Henriette Starke and Dr. Traugott Ullrich again. Jörg Wieczorek was confirmed as Chairman of the Board.
In the public part of the general meeting, Prof. Udo Di Fabio (retired judge of the Federal Constitutional Court) discussed his thoughts on the legal framework for reducing pharmaceutical residues in the environment. Dr. Florian Schmidt, Deputy Head of Unit, DG SANTE, European Commission, reflected on the impact of the EU pharmaceutical strategy on German pharmaceutical manufacturers and addressed in particular the expected revision of European pharmaceutical legislation. Dr. Christoph Krupp, head of the Vaccine Production Taskforce at the German Federal Ministry of Economics and Technology, spoke about ensuring the supply of medicines. The President of the German Pharmacists' Association (ABDA), Gabriele Regina Overwiening, gave a presentation on the future of the pharmacy in times of digitalization, which was followed by a discussion with Dr. Peter Schreiner, Chairman of the Management Board at the health platform gesund.de, and BAH Board Chairman Jörg Wieczorek. Finally, company founder and author Fränzi Kühne presented her thoughts on shaping transformation processes.
Best of 66th General Meeting in 2020